JP2006512413A5 - - Google Patents

Download PDF

Info

Publication number
JP2006512413A5
JP2006512413A5 JP2005502554A JP2005502554A JP2006512413A5 JP 2006512413 A5 JP2006512413 A5 JP 2006512413A5 JP 2005502554 A JP2005502554 A JP 2005502554A JP 2005502554 A JP2005502554 A JP 2005502554A JP 2006512413 A5 JP2006512413 A5 JP 2006512413A5
Authority
JP
Japan
Prior art keywords
types
group
hpv
use according
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005502554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512413A (ja
JP5475939B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/014562 external-priority patent/WO2004056389A1/en
Publication of JP2006512413A publication Critical patent/JP2006512413A/ja
Publication of JP2006512413A5 publication Critical patent/JP2006512413A5/ja
Application granted granted Critical
Publication of JP5475939B2 publication Critical patent/JP5475939B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2005502554A 2002-12-20 2003-12-18 Hpv−16およびhpv−18l1vlpワクチン Expired - Lifetime JP5475939B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US60/435,035 2002-12-20
US49665303P 2003-08-20 2003-08-20
US60/496,653 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (3)

Publication Number Publication Date
JP2006512413A JP2006512413A (ja) 2006-04-13
JP2006512413A5 true JP2006512413A5 (enExample) 2007-01-25
JP5475939B2 JP5475939B2 (ja) 2014-04-16

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005502554A Expired - Lifetime JP5475939B2 (ja) 2002-12-20 2003-12-18 Hpv−16およびhpv−18l1vlpワクチン

Country Status (28)

Country Link
US (2) US20060251676A1 (enExample)
EP (1) EP1572233B1 (enExample)
JP (1) JP5475939B2 (enExample)
KR (3) KR20050086924A (enExample)
AP (1) AP2005003347A0 (enExample)
AR (1) AR042530A1 (enExample)
AT (1) ATE503492T1 (enExample)
AU (1) AU2003293942B2 (enExample)
BE (3) BE2015C068I2 (enExample)
BR (1) BR0317544A (enExample)
CA (1) CA2510457C (enExample)
CY (1) CY1111552T1 (enExample)
DE (1) DE60336581D1 (enExample)
DK (1) DK1572233T3 (enExample)
EA (2) EA009179B1 (enExample)
EC (1) ECSP055869A (enExample)
IL (1) IL169085A (enExample)
IS (1) IS2811B (enExample)
MA (1) MA27581A1 (enExample)
MX (1) MXPA05006764A (enExample)
MY (1) MY144492A (enExample)
NO (1) NO20052846L (enExample)
NZ (1) NZ540811A (enExample)
OA (1) OA13147A (enExample)
PL (1) PL215257B1 (enExample)
PT (1) PT1572233E (enExample)
TW (1) TWI349557B (enExample)
WO (1) WO2004056389A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
RU2420313C2 (ru) * 2004-06-16 2011-06-10 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114273A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
BRPI0811016B1 (pt) * 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
WO2010099580A1 (en) 2009-03-05 2010-09-10 Jenny Colleen Mccloskey Treatment of infection
CN102215861B (zh) * 2009-06-19 2014-10-08 艾金株式会社 宫颈癌疫苗
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
MY195018A (en) 2014-10-24 2023-01-03 Hpvvax Llc Cancer and skin lesion treatment
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EP3305320B1 (en) * 2015-06-02 2024-02-07 Terumo Kabushiki Kaisha Aluminum-containing adjuvant composition, and vaccine composition containing same
JP2021514666A (ja) 2018-03-06 2021-06-17 プレシゲン,インコーポレイテッド B型肝炎ワクチンおよびその使用
KR20250136930A (ko) * 2018-03-06 2025-09-16 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
US11771754B2 (en) * 2018-06-04 2023-10-03 Xiamen University Mutant of L1 protein of human papillomavirus type 18
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
EP1015561B1 (en) 1997-09-05 2006-07-19 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
EP1150712B1 (en) * 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
BR0111956A (pt) * 2000-06-26 2003-05-13 Stressgen Biotechnologies Corp Tratamento do vìrus do papiloma humano

Similar Documents

Publication Publication Date Title
JP2006512413A5 (enExample)
Lowy et al. Prophylactic human papillomavirus vaccines
Yousefi et al. An update on human papilloma virus vaccines: history, types, protection, and efficacy
CA2510457A1 (en) Hpv-16 and -18 l1 vlp vaccine
US10046026B2 (en) Papillomavirus-like particles (VLP) as broad spectrum human papillomavirus (HPV) vaccines
Gambhira et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2
JP6029631B2 (ja) ヒトパピローマウイルス感染症の治療又は予防のための複数型hpvペプチド組成物及び方法
JP2008534467A5 (enExample)
AU2008226974B2 (en) Papillomavirus vaccine compositions
Campo et al. Papillomavirus prophylactic vaccines: established successes, new approaches
Stanley Prophylactic HPV vaccines
Kalnin et al. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes
EA201170264A1 (ru) Вакцина против hpv
Roden et al. The impact of preventive HPV vaccination
JP2008539184A5 (enExample)
Mandic Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines
JP2013540421A5 (enExample)
HRP20120930T1 (hr) Cjepivo protiv hpv16 i hpv18 i još najmanje jednog tipa hpv, kojeg se bira između hpv31, 45 ili 52
JP2008539182A5 (enExample)
CN101116745B (zh) 人乳头瘤病毒的病毒样颗粒疫苗
EA202190441A1 (ru) Терапия папилломавирусных инфекций человека высокого риска
Sultana Human Papilloma Virus Vaccine for Cervical Cancer Prevention
Shah et al. Recurrent respiratory papillomatosis: bright prospects for vaccine-based prevention
Hariharan et al. Genotypes of the human papillomavirus: Relevance to Indian field trials of the vaccine
Takehara et al. Human Papillomavirus Vaccine: Its Application and Perspective